Yoshihisa Akiomi, Suzuki Satoshi, Yamauchi Hiroyuki, Sato Takamasa, Oikawa Masayoshi, Kobayashi Atsushi, Yamaki Takayoshi, Sugimoto Koichi, Kunii Hiroyuki, Nakazato Kazuhiko, Suzuki Hitoshi, Saitoh Shu-Ichi, Takeishi Yasuchika
Department of Cardiology and Hematology, Fukushima Medical University, Fukushima, Japan.
Department of Advanced Cardiac Therapeutics, Fukushima Medical University, Fukushima, Japan.
Clin Cardiol. 2015 Jul;38(7):413-21. doi: 10.1002/clc.22412. Epub 2015 May 12.
Right-heart dysfunction is associated with poor prognosis in heart failure with preserved left ventricular ejection fraction (HFpEF). It remains unclear whether sleep-disordered breathing (SDB) treatment using positive airway pressure (PAP) improves right-heart and pulmonary function and exercise capacity and reduces mortality rates of HFpEF patients.
PAP may improve right-heart and pulmonary function, exercise capacity and prognosis in HFpEF patients with SDB.
One hundred nine consecutive patients with HFpEF (left ventricular ejection fraction >50%) and moderate to severe SDB (apnea-hypopnea index ≥15/h) treated with medications were divided into 2 groups: 31 patients with PAP (PAP group) and 78 patients without PAP (non-PAP group). Right ventricular fractional area change (RV-FAC), tricuspid valve regurgitation pressure gradient (TR-PG), tricuspid valve E/E', forced expiratory volume in 1 second/forced vital capacity (FEV1 /FVC), percentage of vital capacity, and peak VO2 were determined before and 6 months later, and all-cause mortality was followed up for 916 days.
All parameters improved in the PAP group (RV-FAC, 36.0% -46.5%; TR-PG, 31.1 mm Hg-22.4 mm Hg; tricuspid valve E/E', 7.8-5.1; FEV1 /FVC, 83.9%-89.8%; percentage of vital capacity, 83.5%-89.9%; and peak VO2 , 16.6 mL/kg/min-19.6 mL/kg/min; P <0.05, respectively) but not in the non-PAP group. Importantly, all-cause mortality was significantly lower in the PAP group than in the non-PAP group (0% vs 12.8%; log-rank P = 0.014).
Positive airway pressure improves right-heart and pulmonary function and exercise capacity and may reduce all-cause mortality in patients with HFpEF and SDB.
在左心室射血分数保留的心力衰竭(HFpEF)患者中,右心功能不全与预后不良相关。目前尚不清楚使用气道正压通气(PAP)治疗睡眠呼吸紊乱(SDB)是否能改善右心和肺功能、运动能力并降低HFpEF患者的死亡率。
PAP可能改善合并SDB的HFpEF患者的右心和肺功能、运动能力及预后。
109例连续接受药物治疗的HFpEF(左心室射血分数>50%)和中重度SDB(呼吸暂停低通气指数≥15次/小时)患者被分为两组:31例接受PAP治疗的患者(PAP组)和78例未接受PAP治疗的患者(非PAP组)。在治疗前及治疗6个月后测定右心室面积变化分数(RV-FAC)、三尖瓣反流压力阶差(TR-PG)、三尖瓣E/E'、第1秒用力呼气容积/用力肺活量(FEV1/FVC)、肺活量百分比和峰值VO2,并对全因死亡率进行916天的随访。
PAP组所有参数均有改善(RV-FAC,从36.0%提高到46.5%;TR-PG,从31.1 mmHg降至22.4 mmHg;三尖瓣E/E',从7.8降至5.1;FEV1/FVC,从83.9%提高到89.8%;肺活量百分比,从83.5%提高到89.9%;峰值VO2,从16.6 mL/kg/min提高到19.6 mL/kg/min;P均<0.05),而非PAP组无改善。重要的是,PAP组的全因死亡率显著低于非PAP组(0% vs 12.8%;对数秩检验P = 0.014)。
气道正压通气可改善合并SDB的HFpEF患者的右心和肺功能以及运动能力,并可能降低全因死亡率。